Uric acid and diabetes: Is there a link?

Current Pharmaceutical Design

Volumn 19, Issue 27, 2013, Pages 4930-4937

  Katsiki, Niki ^a   Papanas, Nikolaos ^b   Fonseca, Vivian A ^c   Maltezos, Efstratios ^b   Mikhailidis, Dimitri P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Diabetic complications; Drugs; Type 1 diabetes; Type 2 diabetes; Uric acid

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALLOPURINOL; ATORVASTATIN; DAPAGLIFLOZIN; DIURETIC AGENT; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; METFORMIN; NICOTINIC ACID; PIOGLITAZONE; SALICYLIC ACID; SIMVASTATIN; TETRAHYDROLIPSTATIN; THIAZIDE DIURETIC AGENT; URIC ACID;

ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; DIABETIC ANGIOPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DRUG MEGADOSE; GOUT; HUMAN; HYPERURICEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DYSFUNCTION; LOW DRUG DOSE; METABOLIC SYNDROME X; MICROALBUMINURIA; NEPHROLITHIASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; STONE FORMATION; URIC ACID BLOOD LEVEL;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; DIABETIC NEPHROPATHIES; EVIDENCE-BASED MEDICINE; HUMANS; HYPERURICEMIA; METABOLIC SYNDROME X; OBESITY; URIC ACID;

EID: 84881320152     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319270016     Document Type: Article

References (146)

1. Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 2006; 55: 1293-301.
2. Moriarity JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WD. Serum uric acid and risk of coronary heart disease: Atherosclerosis risk in communities (ARIC) study. Ann Epidemiol 2000; 10: 136-43.
3. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: The NHANES I epidemiologic follow-up study, 1971-1992. National health and nutrition examination survey. JAMA 2000; 283: 2404-10.
4. Daskalopoulou SS, Athyros VG, Elisaf M, Mikhailidis DP. Uric acid levels and vascular disease. Curr Med Res Opin 2004; 20: 951-4.
5. Agamah ES, Srinivasan SR, Webber LS, Berenson GS. Serum uric acid and its relation to cardiovascular disease risk factors in children and young adults from a biracial community: the Bogalusa Heart Study. J Lab Clin Med. 1991; 118: 241-9.
6. Lioudaki E, Vrentzos GE, Mavrogeni H, et al. Prevalence of metabolic syndrome according to different definitions in a hypertensive population. Angiology 2012; 63: 39-47.
7. Athyros VG, Ganotakis ES, Tziomalos K, et al. Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. Curr Med Res Opin 2010; 26: 713-9.
8. Athyros VG, Bouloukos VI, Pehlivanidis AN, et al; MetS-Greece Collaborative Group. The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study. Diabetes Obes Metab 2005; 7: 397-405.
9. Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med 2011; 9: 48.
10. Cook DG, Shaper AG, Thelle DS, Whitehead TP. Serum uric acid, serum glucose and diabetes: relationships in a population study. Postgrad Med J 1986; 62: 1001-6.
11. Whitehead TP, Jungner I, Robinson D, Kolar W, Pearl A, Hale A. Serum urate, serum glucose and diabetes. Ann Clin Biochem 1992; 29: 159-61.
12. Hairong Nan, Zengchang Pang, Shaojie Wang, et al. Serum uric acid, plasma glucose and diabetes. Diab Vasc Dis Res 2010; 7: 40-6.
13. Goembiewska E, Ciechanowski K, Safranow K, Kedzierska K, Kabat-Koperska J. Renal handling of uric acid in patients with type 1 diabetes in relation to glycemic control. Arch Med Res 2005; 36: 32-5.
14. Choi HK, Ford ES. Haemoglobin A1c, fasting glucose, serum Cpeptide and insulin resistance in relation to serum uric acid levels--the Third National Health and Nutrition Examination Survey. Rheumatology (Oxford). 2008; 47: 713-7.
15. Mohora M, Vîrgolici B, Coman A, et al. Diabetic foot patients with and without retinopathy and plasma oxidative stress. Rom J Intern Med. 2007; 45: 51-7.
16. Ficociello LH, Rosolowsky ET, Niewczas MA, et al. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care 2010; 33: 1337-43.
17. Lehto S, Niskanen L, Ronnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with noninsulin-dependent diabetes mellitus. Stroke 1998; 29: 635-9.
18. Tseng CH. Independent association of uric acid levels with peripheral arterial disease in Taiwanese patients with type 2 diabetes. Diabet Med 2004; 21: 724-9.
19. Ioachimescu AG, Brennan DM, Hoar BM, Kashyap SR, Hoogwerf BJ. Serum uric acid, mortality and glucose control in patients with Type 2 diabetes mellitus: a PreCIS database study. Diabet Med 2007; 24: 1369-74.
20. Ong G, Davis WA, Davis TM. Serum uric acid does not predict cardiovascular or all-cause mortality in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 2010; 53: 1288-94.
21. Kylin E. Studien über das Hypertonie-hyperglykämiehyperurikämiesyndrom. Zentralblatt für Innere Medizin 1923; 44: 105-27.
22. Engelhardt HT, Wagner EL. Gout, diabetes mellitus and obesity, a poorly appreciated syndrome. South Med J 1950; 43: 51-3.
23. Weiss TE, Segaloff A, Moore C. Gout and diabetes. Metabolism 1957; 6: 103-6.
24. Beckett AG, Lewis JG. Gout and the serum uric acid in diabetes mellitus. Q J Med 1960; 29: 443-58.
25. Mikkelsen WM. The possible association of hyperuricemia and/or gout with diabetes mellitus. Arthritis Rheum 1965; 8: 853-64.
26. Medalie JH, Papier CM, Goldbourt U, Herman JB. Major factors in the development of diabetes mellitus in 10, 000 men. Arch Intern Med 1975; 135: 811-7.
27. Herman JB, Medalie JH, Goldbourt U. Diabetes, prediabetes and uricaemia. Diabetologia 1976; 12: 47-52.
28. Yano K, Rhoads G, Kagan A. Epidemiology of serum uric acid among 8000 Japanese-American men in Hawaii. J Chronic Dis 1977; 30: 171-84.
29. Herman JB, Goldbourt U. Uric acid and diabetes: observations in a population study. Lancet 1982; 2: 240-3.
30. Yuan HJ, Yang XG, Shi XY, Tian R, Zhao ZG. Association of serum uric acid with different levels of glucose and related factors. Chin Med J (Engl). 2011; 124: 1443-8.
31. Tuomilehto J, Zimmet P, Wolf E, Taylor R, Ram P, King H. Plasma uric acid level and its association with diabetes mellitus and some biologic parameters in a biracial population of Fiji. Am J Epidemiol 1988; 127: 321-36.
32. Nan H, Dong Y, Gao W, Tuomilehto J, Qiao Q. Diabetes associated with a low serum uric acid level in a general Chinese population. Diabetes Res Clin Pract 2007; 76: 68-74.
33. Modan M, Halkin H, Karasik A, Lusky A. Elevated serum uric acid-a facet of hyperinsulinaemia. Diabetologia 1987; 30: 713-8.
34. Chou P, Lin KC, Lin HY, Tsai ST. Gender differences in the relationships of serum uric acid with fasting serum insulin and plasma glucose in patients without diabetes. J Rheumatol 2001; 28: 571-6.
35. Golik A, Weissgarten J, Cotariu D, et al. Renal uric acid handling in non-insulin-dependent diabetic patients with elevated glomerular filtration rates. Clin Sci 1993; 85: 713-6.
36. Boner G, Rieselbach RE. The effect of glucose upon reabsorptive transport of urate by the kidney. Adv Exp Med Biol 1974; 41: 781-7.
37. Herman JB, Keynan A. Hyperglycemia and uric acid. Isr J Med Sci 1969; 5: 1048-52.
38. Gotfredsen A, McNair P, Christiansen C, Transbol I. Renal hypouricaemia in insulin treated diabetes mellitus. Clin Chim Acta 1982; 120: 355-61.
39. Erdberg A, Boner G, van Dyk DJ, Carel R. Urine uric acid excretion in patients with insulin-dependent diabetes mellitus. Nephron 1992; 60: 134-7.
40. González-Sicilia L, García-Estañ J, Martínez-Blázquez A, Fernández-Pardo J, Quiles JL, Hernández J. Renal metabolism of uric acid in type I insulin-dependent diabetic patients: relation to metabolic compensation. Horm Metab Res 1997; 29: 520-3.
41. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purinerich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004; 350: 1093-103.
42. Fung TT, Schulze M, Manson JE, Willett WC, Hu FB. Dietary patterns, meat intake, and the risk of type 2 diabetes in women. Arch Intern Med 2004; 164: 2235-40.
43. Song Y, Manson JE, Buring JE, Liu S. A prospective study of red meat consumption and type 2 diabetes in middle-aged and elderly women: the women's health study. Diabetes Care 2004; 27: 2108-15.
44. Holbrook TL, Barrett-Connor E, Wingard DL. A prospective population-based study of alcohol use and non-insulin-dependent diabetes mellitus. Am J Epidemiol 1990; 132: 902-9.
45. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366: 1059-62.
46. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011; 11: 85-97.
47. Katsiki N, Mikhailidis DP, Gotzamani-Psarrakou A, Yovos JG, Karamitsos D. Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus. Expert Opin Ther Targets 2011; 15: 401-20.
48. Katsiki N, Yovos JG, Gotzamani-Psarrakou A, Karamitsos DT. Adipokines and vascular risk in type 2 diabetes mellitus. Angiology 2011; 62: 601-4.
49. Park CS, Ihm SH, Park HJ, et al. Relationship between plasma adiponectin, retinol-binding protein 4 and uric Acid in hypertensive patients with metabolic syndrome. Korean Circ J 2011; 41: 198-202.
50. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991; 266: 3008-11.
51. Ford ES, Li C, Cook S, Choi HK. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation 2007; 115: 2526-32.
52. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007; 57: 109-15.
53. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007; 120: 442-7.
54. Forman JP, Choi H, Curhan GC. Uric acid and insulin sensitivity and risk of incident hypertension. Arch Intern Med 2009; 169: 155-62.
55. Nakanishi N, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, Tatara K. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol 2003; 18: 523-30.
56. Tinahones FJ, Cardona F, Rojo-Martínez G, et al. Decreased levels of uric acid after oral glucose challenge is associated with triacylglycerol levels and degree of insulin resistance. Br J Nutr 2008; 99: 44-8.
57. Tsunoda S, Kamide K, Minami J, Kawano Y. Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulinsensitizing agent. Am J Hypertens 2002; 15: 697-701.
58. Muscelli E, Natali A, Bianchi S, et al. Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens 1996; 9: 746-52.
59. Sui X, Church TS, Meriwether RA, Lobelo F, Blair SN. Uric acid and the development of metabolic syndrome in women and men. Metabolism 2008; 57: 845-52.
60. Ryu S, Song J, Choi BY, et al. Incidence and risk factors for metabolic syndrome in Korean male workers, ages 30 to 39. Ann Epidemiol 2007; 17: 245-52.
61. Carnethon MR, Fortmann SP, Palaniappan L, Duncan BB, Schmidt MI, Chambless LE. Risk factors for progression to incident hyperinsulinemia: the Atherosclerosis Risk in Communities Study, 1987-1998. Am J Epidemiol 2003; 158: 1058-67.
62. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003; 42: 474-80.
63. Nakanishi N, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, Tatara K. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol 2003; 18: 523-30.
64. Boyko EJ, de Courten M, Zimmet PZ, Chitson P, Tuomilehto J, Alberti KG. Features of the metabolic syndrome predict higher risk of diabetes and impaired glucose tolerance: a prospective study in Mauritius. Diabetes Care 2000; 23: 1242-8.
65. Kodama S, Saito K, Yachi Y, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care 2009; 32: 1737-42
66. Cardona F, Rojo-Martínez G, de la Cruz Almaraz M, Soriguer F, García-Fuentes E, Tinahones FJ. Uric acid predicts type 2 diabetes mellitus in the general population. Endocrinol Nutr 2009; 56: 66-70.
67. Bhole V, Choi JW, Kim SW, de Vera M, Choi H. Serum uric acid levels and the risk of type 2 diabetes: a prospective study. Am J Med 2010; 123: 957-61.
68. Kramer CK, von Mühlen D, Jassal SK, Barrett-Connor E. Serum uric acid levels improve prediction of incident type 2 diabetes in individuals with impaired fasting glucose: the Rancho Bernardo Study. Diabetes Care 2009; 32: 1272-3.
69. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 2008; 75: 721-8.
70. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007; 191: 235-40.
71. Athyros VG, Tziomalos K, Gossios TD, et al; GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376: 1916-22.
72. Lioudaki E, Ganotakis ES, Mikhailidis DP. Liver enzymes: potential cardiovascular risk markers? Curr Pharm Des 2011; 17: 3632-43.
73. Lee YJ, Lee HR, Lee JH, Shin YH, Shim JY. Association between serum uric acid and non-alcoholic fatty liver disease in Korean adults. Clin Chem Lab Med 2010; 48: 175-80.
74. Xu C, Yu C, Xu L, Miao M, Li Y. High serum uric acid increases the risk for nonalcoholic fatty liver disease: a prospective observational study. PLoS One 2010; 5: e11578.
75. Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J Hepatol 2009; 50: 1029-34.
76. Lee JW, Cho YK, Ryan M, et al. Serum uric acid as a predictor for the development of nonalcoholic fatty liver disease in apparently healthy subjects: a 5-year retrospective cohort study. Gut Liver 2010; 4: 378-83.
77. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Hyperuricaemia and Non-Alcoholic Fatty Liver Disease (NAFLD): A Relationship with Implications for Vascular Risk? Curr Vasc Pharmacol 2011; 9: 698-705.
78. Petta S, Cammà C, Cabibi D, Di Marco V, Craxì A. Hyperuricemia is associated with histological liver damage in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2011; 34: 757-66.
79. Afzali A, Weiss NS, Boyko EJ, Ioannou GN. Association between serum uric acid level and chronic liver disease in the United States. Hepatology 2010; 52: 578-89.
80. Ruilope LM, Garcia-Puig J. Hyperuricemia and renal function. Curr Hypertens Rep 2001; 3: 197-202.
81. Zapolski T, Wacíski P, Kondracki B, Rychta E, Buraczyska MJ, Wysokíski A. Uric acid as a link between renal dysfunction and both pro-inflammatory and prothrombotic state in patients with metabolic syndrome and coronary artery disease. Kardiol Pol 2011; 69: 319-26.
82. Cai XL, Han XY, Ji LN. Association between serum uric acid and different states of glucose metabolism and glomerular filtration rate. Chin Med J (Engl) 2010; 123: 3118-22.
83. Hayden MR, Tyagi SC. Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutr Metab (Lond) 2004; 1: 10.
84. Gluba A, Mikhailidis DP, Lip GY, Hannam S, Rysz J, Banach M. Metabolic syndrome and renal disease. Int J Cardiol 2012 Feb 2. [Epub ahead of print]
85. Johnson RJ, Perez-Pozo SE, Sautin YY, et al. Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes? Endocr Rev 2009; 30: 96-116.
86. Florentin M, Liberopoulos EN, Kei A, Mikhailidis DP, Elisaf MS. Pleiotropic Effects of Nicotinic Acid: Beyond High Density Lipoprotein Cholesterol Elevation. Curr Vasc Pharmacol 2011; 9: 385-400.
87. Caspi D, Lubart E, Graff E, Habot B, Yaron M, Segal R. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum 2000; 43: 103-8.
88. Daskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des 2005; 11: 4161-4175.
89. Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother 2008; 9: 1087-108.
90. Gokcel A, Gumurdulu Y, Karakose H, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 2002; 4: 49-55.
91. Magoula I, Tsapas G, Paletas K, Mavromatidis K. Insulindependent diabetes and renal hypouricaemia. Nephron 1991; 59: 21-6.
92. Hovind P, Rossing P, Tarnow L, Johnson RJ, Parving HH. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes 2009; 58: 1668-71.
93. Jalal DI, Rivard CJ, Johnson RJ, et al. Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study. Nephrol Dial Transplant 2010; 25: 1865-9.
94. Huang EJ, Kuo WW, Chen YJ, et al. Homocysteine and other biochemical parameters in Type 2 diabetes mellitus with different diabetic duration or diabetic retinopathy. Clin Chim Acta 2006; 366: 293-8.
95. Cai XL, Wang F, Ji LN. Risk factors of diabetic retinopathy in type 2 diabetic patients. Chin Med J (Engl) 2006; 119: 822-6.
96. Tapp RJ, Shaw JE, de Courten MP, Dunstan DW, Welborn TA, Zimmet PZ; AusDiab Study Group. Foot complications in Type 2 diabetes: an Australian population-based study. Diabet Med 2003; 20: 105-13.
97. Papanas N, Demetriou M, Katsiki N, et al. Increased serum levels of uric acid are associated with sudomotor dysfunction in subjects with type 2 diabetes mellitus. Exp Diabetes Res. 2011; 2011: 346051.
98. Rosolowsky ET, Ficociello LH, Maselli NJ, et al. High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 2008; 3: 706-13
99. Perkins BA, Krolewski AS. Early nephropathy in type 1 diabetes: the importance of early renal function decline. Curr Opin Nephrol Hypertens 2009; 18: 233-40.
100. Molnár M, Wittmann I, Nagy J. Prevalence, course and risk factors of diabetic nephropathy in type-2 diabetes mellitus. Med Sci Monit 2000; 6: 929-36.
101. Bo S, Cavallo-Perin P, Gentile L, Repetti E, Pagano G. Hypouricemia and hyperuricemia in type 2 diabetes: two different phenotypes. Eur J Clin Invest 2001; 31: 318-21.
102. Fukui M, Tanaka M, Shiraishi E, et al. Serum uric acid is associated with microalbuminuria and subclinical atherosclerosis in men with type 2 diabetes mellitus. Metabolism 2008; 57: 625-9.
103. Tseng CH. Correlation of uric acid and urinary albumin excretion rate in patients with type 2 diabetes mellitus in Taiwan. Kidney Int 2005; 68: 796-801.
104. Fu CC, Wu DA, Wang JH, Yang WC, Tseng CH. Association of C-reactive protein and hyperuricemia with diabetic nephropathy in Chinese type 2 diabetic patients. Acta Diabetol 2009; 46: 127-34.
105. Kosugi T, Nakayama T, Heinig M, et al. Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. Am J Physiol Renal Physiol 2009; 297: F481-8.
106. Momeni A, Shahidi S, Seirafian S, Taheri S, Kheiri S. Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients. Iran J Kidney Dis 2010; 4: 128-32.
107. Montalcini T, Gorgone G, Gazzaruso C, Sesti G, Perticone F, Pujia A. Relation between serum uric acid and carotid intima-media thickness in healthy postmenopausal women. Intern Emerg Med 2007; 2: 19-23.
108. Guo L, Cheng Y, Wang X, et al. Association between microalbuminuria and cardiovascular disease in type 2 diabetes mellitus of the Beijing Han nationality. Acta Diabetol. 2010 Jul 1. [Epub ahead of print]
109. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417, 734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 2009; 266: 558-70.
110. Milionis HJ, Kalantzi KJ, Goudevenos JA, Seferiadis K, Mikhailidis DP, Elisaf MS. Serum uric acid levels and risk for acute ischaemic non-embolic stroke in elderly subjects. J Intern Med 2005; 258: 435-41.
111. Milionis HJ, Rizos E, Goudevenos J, Seferiadis K, Mikhailidis DP, Elisaf MS. Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects. Stroke 2005; 36: 1372-6.
112. Niskanen LK, Laaksonen DE, Nyyssönen K, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middleaged men: a prospective cohort study. Arch Intern Med 2004; 164: 1546-51.
113. De Luca G, Secco GG, Santagostino M, et al; on behalf of the Novara Atherosclerosis Study Group (NAS). Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. Nutr Metab Cardiovasc Dis. 2010 Dec 24. [Epub ahead of print]
114. Rathmann W, Hauner H, Dannehl K, Gries FA. Association of elevated serum uric acid with coronary heart disease in diabetes mellitus. Diabete Metab 1993; 19: 159-66.
115. Seghieri G, Moruzzo D, Fascetti S, et al. Increase in serum uric acid is selectively associated with stroke in type 2 diabetes. Diabetes Care 2002; 25: 1095.
116. Wun YT, Chan CS, Lui CS. Hyperuricaemia in Type 2 diabetes mellitus. Diabetes Nutr Metab 1999; 12: 286-91.
117. Newman EJ, Rahman FS, Lees KR, Weir CJ, Walters MR. Elevated serum urate concentration independently predicts poor outcome following stroke in patients with diabetes. Diabetes Metab Res Rev 2006; 22: 79-82.
118. Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003; 34: 1951-6.
119. Karagiannis A, Mikhailidis DP, Tziomalos K, et al. Serum uric acid as an independent predictor of early death after acute stroke. Circ J 2007; 71: 1120-7.
120. So A, Thorens B. Uric acid transport and disease. J Clin Invest 2010; 120: 1791-9
121. Hall PM. Nephrolithiasis: treatment, causes, and prevention. Cleve Clin J Med 2009; 76: 583-91.
122. Takahashi S, Inokuchi T, Kobayashi T, et al. Relationship between insulin resistance and low urinary pH in patients with gout, and effects of PPARalpha agonists on urine pH. Horm Metab Res 2007; 39: 511-4.
123. Liebman SE, Taylor JG, Bushinsky DA. Uric acid nephrolithiasis. Curr Rheumatol Rep 2007; 9: 251-7.
124. Lieske JC, de la Vega LS, Gettman MT, et al. Diabetes mellitus and the risk of urinary tract stones: a population-based case-control study. Am J Kidney Dis 2006; 48: 897-904.
125. Duvdevani M, Nott L, Ray AA, Ko R, Denstedt JD, Razvi H. Percutaneous nephrolithotripsy in patients with diabetes mellitus. J Endourol 2009; 23: 21-6.
126. Daudon M, Traxer O, Conort P, Lacour B, Jungers P. Type 2 diabetes increases the risk for uric acid stones. J Am Soc Nephrol 2006; 17: 2026-33.
127. Daudon M, Lacour B, Jungers P. High prevalence of uric acid calculi in diabetic stone formers. Nephrol Dial Transplant 2005; 20: 468-9.
128. Sakhaee K, Maalouf NM. Metabolic syndrome and uric acid nephrolithiasis. Semin Nephrol 2008; 28: 174-80.
129. Maalouf NM. Metabolic syndrome and the genesis of uric acid stones. J Ren Nutr 2011; 21: 128-31
130. Suzuki I, Yamauchi T, Onuma M, Nozaki S. Allopurinol, an inhibitor of uric acid synthesis--can it be used for the treatment of metabolic syndrome andrelated disorders? Drugs Today (Barc) 2009; 45: 363-78.
131. Dogan A, Yarlioglues M, Kaya MG, et al. Effect of long-term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patients. Blood Press 2011; 20: 182-7.
132. Kelkar A, Kuo A, Frishman WH. Allopurinol as a cardiovascular drug. Cardiol Rev 2011; 19: 265-71.
133. Puddu P, Puddu GM, Cravero E, Vizioli L, Muscari A. The relationships among hyperuricemia, endothelial dysfunction, and cardiovascular diseases: Molecular mechanisms and clinical implications. J Cardiol. 2012 Mar 5. [Epub ahead of print]
134. Halvorsen B, Heggen E, Ueland T, et al. Treatment with the PPARgamma agonist rosiglitazone downregulates interleukin-1 receptor antagonist in individuals with metabolic syndrome. Eur J Endocrinol 2010; 162: 267-73.
135. Katsiki N, Papanas N, Mikhailidis DP. Dapagliflozin: more than just another oral glucose-lowering agent? Expert Opin Investig Drugs 2010; 19: 1581-9.
136. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007; 22: 118-27.
137. Athyros VG, Elisaf M, Papageorgiou AA, et al; GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronaryheart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004; 43: 589-99.
138. Youssef F, Gupta P, Seifalian AM, Myint F, Mikhailidis DP, Hamilton G. The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology 2004; 55: 53-62.
139. Nakou ES, Filippatos TD, Georgoula M, et al. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin 2008; 24: 1919-29.
140. Derosa G, Maffioli P. Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients. Expert Rev Cardiovasc Ther 2010; 8: 835-43.
141. Høieggen A, Alderman MH, Kjeldsen SE, et al; LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041-9.
142. Milionis HJ, Rizos E, Kostapanos M, et al. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin 2006; 22: 1123-31.
143. Athyros VG, Karagiannis A, Ganotakis ES, et al; Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT) Collaborative Group. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin 2011; 27: 1659-68.
144. Onat A. Metabolic syndrome: nature, therapeutic solutions and options. Expert Opin Pharmacother 2011; 12: 1887-1900.
145. Goldfine AB, Fonseca V, Shoelson SE. Therapeutic approaches to target inflammation in type 2 diabetes. Clin Chem 2011; 57: 162-7.
146. Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011; 305: 2525-31.